|
|
Research Studies at Stanford
Study 1. Metabolic Effects of Antipsychotics and Treatment with Aripiprazole. This study focuses on what has become the major concern with the new generation of antipsychotics, i.e. weight gain, which has the potential to increase the risk of cardiovascular complications. The recent introduction of a third generation of antipsychotics, with a different mechanism of action, presents a possible new opportunity for managing this significant side effect. The study we are conducting will include both males and females, 18-65 years old, who have a diagnosis of schizophrenia or schizoaffective disorder, are moderately to severely overweight, and currently are receiving a stable dose of one or more antipsychotics (clozapine, risperidone, olanzapine, quetiapine or ziprasidone). After consultation and a workup, we will do testing of metabolic parameters, and switch patients to aripiprazole from their current antipsychotic examining weight changes and efficacy of medication.
Study 2. Treatment of Schizophrenia with OCD Symptoms. The goal of this study is to test the effectiveness of an antipsychotic, aripiprazole, as a monotherapy in patients whose symptoms of schizophrenia are concurrent with symptoms typical of obsessive-compulsive disorder. For non-responders, we will add an antidepressant, citalopram. To be considered for this study, a patient must be 18 to 65 years old, have a diagnosis of schizophrenia or schizoaffective disorder, and have some symptoms of obsessive-compulsive disorder.
Study 3. Atypical Antipsychotics Plus Concomitant Mood Stabilizers for Treatment of Schizophrenia or Schizoaffective Disorder. We know that a new generation of antipsychotics can improve the outcome of schizophrenia. However, often there is only a partial response. Accordingly, we will examine whether the addition of a mood stabilizer to an antipsychotic medication will result in an improvement in the symptoms and function. The treatment includes divalproex sodium or lamotrigine as an add-on therapy to a current antipsychotic in a double-blind, placebo-controlled, 4 month study. The study will include both males and females, 18-65 years old, who are suffering from schizophrenia or schizoaffective disorder and taking only one of the following antipsychotic medications for at least 30 days: risperidone, olanzapine, aripiprazole, clozapine, quetiapine or ziprasidone.
Study 4. Treatment of Schizophrenia Using a New Antipsychotic. We are continuously examining the effectiveness of new antipsychotics as they come to market. We have been funded to examine the long-term safety, efficacy, and tolerability of a new antipsychotic, bifeprunox. Bifeprunox is a dopamine D2 partial agonist and a serotonin 5-HT1A partial agonist. The study includes open-label treatment with bifeprunox for 52 weeks, including 10 days inpatient. The study will include both males and females, 18-65 years old, who are suffering from schizophrenia or schizoaffective disorder, relatively stable and in need of treatment.
For more information on these programs please contact:
Last Updated on 08/21/05 webmaster@namiscc.org |
|
Opinions expressed in this web site do not necessarily reflect the views of NAMI Santa Cruz County, NAMI California or any affiliated organizations. We attempt to present a balanced perspective on issues by presenting multiple viewpoints. Copyright 2005 National Alliance for the Mentally Ill Santa Cruz County, All Rights Reserved. FAIR USE NOTICE: This may contain copyrighted (©) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available to advance understanding of ecological, political, human rights, economic, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml If you wish to use copyrighted material for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner. |
